Pharmacokinetic considerations for antibody drug conjugates (Q38022192)

27 August 2017

title

Pharmacokinetic considerations for antibody drug conjugates (English)

1 reference

27 August 2017

1 reference

1 reference

Kedan Lin

1

1 reference

27 August 2017

Jay Tibbitts

series ordinal

2

1 reference

27 August 2017

publication date

28 June 2012

1 reference

27 August 2017

published in

Pharmaceutical Research

1 reference

27 August 2017

volume

29

1 reference

27 August 2017

issue

9

1 reference

27 August 2017

page(s)

2354-2366

1 reference

Antibody-drug conjugates for cancer therapy

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Antibody targeted drugs as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Immunotherapy: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Improving the efficacy of antibody-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Evidence of neuronal degeneration in C57B1/6 mice infected with the LP-BM5 leukemia retrovirus mixture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Antibody-maytansinoid conjugates designed to bypass multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Future directions in radioimmunotherapy for B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Cancer radioimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Arming antibodies: prospects and challenges for immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Antibody-cytotoxic agent conjugates: preparation and characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Elimination mechanisms of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Effect of Immune Complex Formation on the Distribution of a Novel Antibody to the Ovarian Tumor Antigen CA125

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Contribution of linker stability to the activities of anticancer immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Drug metabolites in safety testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Interspecies scaling of therapeutic monoclonal antibodies: initial look

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Characterization of intact antibody–drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography–mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-012-0800-Y

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

21 January 2018

1 reference

12 December 2020

The pharmacologic basis for antibody-auristatin conjugate activity

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development

1 reference

12 December 2020

Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer

1 reference

12 December 2020

Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study

1 reference

12 December 2020

Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate

1 reference

12 December 2020

Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver

1 reference

12 December 2020

In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate

1 reference

12 December 2020

Radioimmunotherapy of non-Hodgkin's lymphoma: from the 'magic bullets' to 'radioactive magic bullets'.

1 reference

12 December 2020

Clinical immunogenicity specificity assessments: a platform evaluation

1 reference

12 December 2020

Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism

1 reference

12 December 2020

International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice.

1 reference

12 December 2020

Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies

1 reference

12 December 2020

Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.

1 reference

12 December 2020

FDA approves brentuximab vedotin for Hodgkin lymphoma and systemic anaplastic large-cell lymphoma

1 reference

12 December 2020

10.1007/S11095-012-0800-Y

Identifiers

DOI

1 reference

27 August 2017

1 reference